...
首页> 外文期刊>Biosciences Biotechnology Research Asia >Fexofenadine HCl Microspheres - Can it be the First Line therapy for Allergic Disorders ?
【24h】

Fexofenadine HCl Microspheres - Can it be the First Line therapy for Allergic Disorders ?

机译:Fexofenadine HCl Microspheres - Can it be the First Line therapy for Allergic Disorders ?

获取原文
获取原文并翻译 | 示例
           

摘要

Fexofenadine HCl is a second-generation antihistamine which is commonly used for allergic disorders. But it has low bioavailability. Intranasal corticosteroids (INCs) and Immunotherapy and Allergen Specific Immunotherapy (ASIT) are now commonly beingsuggested for the treatment of allergic disorders. Despite the fact that current treatment alternatives have been in use for decades, patient quality of life has remained static. The treatment options are not much explored for their respective adverse effects. Therefore, they are in desperate need of research. Fexofenadine HCl is available in the form of a suspension, tablet, or capsule. In our current study, we have explored whether microspheres can be the perfect dosage form of Fexofenadine HCl to treat allergic disorders considering the pharmacokinetics of the drug, available dosage forms options and the probable side effects of the current therapies.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号